Weger, W; Gruber, B; Ratzinger, G; Sator, PG.
Patient-reported well-being using tildrakizumab in a real-world setting: 28-week interim data in patients with nail psoriasis from the phase IV POSITIVE study
J INVEST DERMATOL. 2023; 143(11):S352-S352.-5th Inflammatory Skin Disease Summit (ISDS); NOV 15-18, 2023; Vienna, AUSTRIA.
[Poster]
Web of Science